Characterization of lung cancers in patients with BRCA germline variants: A multicenter series. (November 2022)

• Record Type: Journal Article
• Authors: Sanchis-Borja, Mateo; Fallet, Vincent; Fabre, Elisabeth; Wislez, Marie; Culine, Stéphane; Zalcman, Gérard; Spano, Jean-Philippe; Buffet, Nathalie Chabbert; Coulet, Florence; Benusiglio, Patrick R.; Cadranel, Jacques
• Is Part Of: Lung cancer. Volume 173(2022)
• Page Start: 67
• Page End: 70
• Publication Date: 2022-11
• Subjects: Lung cancer -- BRCA1 -- BRCA2 -- Germline variants -- Genetic susceptibility to cancer; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2022.09.002
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Association between BRCA 2 germline pathogenic variants and lung cancer has been suggested. Our results seem to show particular lung cancer features in carriers of BRCA2 variants: adenocarcinoma subtype, woman, former or non-smoker. Smoking might be the trigger for a low penetrance cancer predisposing syndrome. In the future, BRCA1/2 studies should consider environmental risk factors, including smoking. Abstract: Introduction: BRCA1 and BRCA2 (BReast CAncer susceptibility genes) are two tumor-suppressor genes associated with the hereditary breast and ovarian cancer susceptibility syndrome. Recent studies also suggest an increased lung adenocarcinoma risk in carriers. Methods: We conducted a multi-center retrospective study in 18 different French pulmonology and/or oncology departments on medico-administrative and clinical data prospectively collected in the Clinical Data Warehouse (CDW) of Greater Paris University Hospitals (Assistance Publique-Hôpitaux de Paris, AP-HP). Clinical characteristics and outcomes of patients with LC and a previously known BRCA1/2gl variant were retrospectively evaluated. Results: 17 patients with LC and known BRCA1/2gl variant were included. Patients were most women, former smokers with localized disease and BRCA2 variants. All LC were adenocarcinoma. For patients with medical history of cancer, median time from the first cancer in the BRCA spectrum and the LC occurrence was 20 years. Median disease-free survival (DFS) and overall survival (OS) in localized tumor (Stage I and II) was not reached and 78.6 months, respectively. In advanced cancer (Stade III and IV) median progression free survival was 9.7 months and median OS was 17.8 months. Univariate OS and DFS/PFS analyses by BRCA status did not find significant differences. Conclusion: Results seem to show particular LC features in carriers of BRCA2 variants: adenocarcinoma subtype, woman, former or non-smoker.